Key facts
- · Type: Amendment first sale 2025-04-17 · Amount sold: $108K · Total offering: $500K · SEC filing
- · Type: Amendment first sale 2025-04-17 · Amount sold: $203K · Total offering: $500K · SEC filing
- · Type: Amendment first sale 2025-04-17 · Amount sold: $108K · Total offering: $150K · SEC filing
- · Type: New offering first sale 2025-04-17 · Amount sold: $108K · SEC filing
Is Mivax Therapeutics, Inc. a real, registered company?
Mivax Therapeutics, Inc. is a registered filer with the SEC (CIK 2066303) and has filed since 2025-05-01. 4 filings are on record, the latest on 2026-01-23.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
How much has Mivax Therapeutics, Inc. raised?
Its new offerings report $108K sold across 1 offering, as its own filings state.
Run the free check on Mivax Therapeutics, Inc. →
SAN FRANCISCO, CALIFORNIA
2024
Biotechnology
4
$108K
Every filing
| Filed | Type | Amount sold | Total offering | Records |
|---|---|---|---|---|
| 2026-01-23 | Amendment first sale 2025-04-17 | $108K | $500K | SEC filing |
| 2026-01-23 | Amendment first sale 2025-04-17 | $203K | $500K | SEC filing |
| 2025-05-02 | Amendment first sale 2025-04-17 | $108K | $150K | SEC filing |
| 2025-05-01 | New offering first sale 2025-04-17 | $108K | — | SEC filing |
Keep reading
More on Mivax Therapeutics, Inc. and the records around it.
Mivax Therapeutics, Inc. elsewhere on the record
- Form D filing May 2025
Watch Mivax Therapeutics, Inc.
Get an email when Mivax Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
What do you want to do with Mivax Therapeutics, Inc.?
Who to contact
- Viraj Deshpande — President and Secretary
- Pragyesh Dhungel — Chief Executive Officer and Treasurer
- Round: Form D/A (amended) filed 2026-01-23
- Amount sold: $108K
- Industry: Biotechnology
- Founded: 2024
- Based: SAN FRANCISCO, CALIFORNIA
People listed
- Viraj Deshpande — President and Secretary
- Pragyesh Dhungel — Chief Executive Officer and Treasurer
- Filing: Form D/A (amended) filed 2026-01-23
- Amount sold: $108K
- Industry group: Biotechnology
- Year formed: 2024
- Based: SAN FRANCISCO, CALIFORNIA
- Entity type: Corporation
We'll show it in your MentionFox inbox when Mivax Therapeutics, Inc. raises, hires or launches. No email unless you switch it on.
Watch Mivax Therapeutics, Inc. →Want the whole picture on Mivax Therapeutics, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Mivax Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Mivax Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
5 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
How the total is counted: the amount sold on each new offering, added together. Amendments are left out, because an amendment restates an offering already counted. A filing whose figures have not been read yet shows a dash and adds nothing.
Every figure here is read from Mivax Therapeutics, Inc.'s own filings with the SEC. The people those filings name are on the team page.